These are drugs that have never been approved by the FDA. No manufacturers were previously approved and no standards have been changed.
The FDA wanted clinical trials on the drugs. There are incentives in place to encourage companies to develop drugs for rare conditions where there are not enough patients to warrant investing in for economic rewards (and yet you envision companies in competition over them). These include grants for the required trials, tax credits for half of the cost of developing the drug, and a seven year monopoly on the drug.